Portal de Periódicos da CAPES

Full-Dose Irradiation for Patients with Invasive Bladder Carcinoma: Clinical and Histological Factors Prognostic of Improved Survival

1985; Lippincott Williams & Wilkins; Volume: 134; Issue: 4 Linguagem: Inglês

10.1016/s0022-5347(17)47381-2

1527-3792

William U. Shipley, Mary Ann Rose, Theresa Perrone, Catherine M. Mannix, Niall M. Heney, George R. Prout,

Lymphoma Diagnosis and Treatment

No AccessJournal of Urology1 Oct 1985Full-Dose Irradiation for Patients with Invasive Bladder Carcinoma: Clinical and Histological Factors Prognostic of Improved Survival William U. Shipley, Mary Ann Rose, Theresa L. Perrone, Catherine M. Mannix, Niall M. Heney, and George R. Prout William U. ShipleyWilliam U. Shipley , Mary Ann RoseMary Ann Rose , Theresa L. PerroneTheresa L. Perrone , Catherine M. MannixCatherine M. Mannix , Niall M. HeneyNiall M. Heney , and George R. ProutGeorge R. Prout View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)47381-2AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail We reviewed the outcome of 55 patients treated from 1974 to 1982 by full-dose radiation therapy (6,400 to 6,800 rad) to identify factors associated with tumor radioresponsiveness and patient cure. All patients had histological proof of muscle invasion by tumor. Of the patients 8 (14 per cent) had clinical stage T2, 29 (53 per cent) stage T3 and 18 (33 per cent) stage T4 disease. Thirteen patients are alive, all but 2 without evidence of cancer. Survivors include 1 of 9 patients who underwent salvage cystectomy for a local recurrence. The actuarial 5-year survival rate for the entire group was 28 per cent, with a corrected survival of 33 per cent. Median survival was 2.3 years. Corrected survival for patients with stages T2 and T3 disease was 45 per cent versus 9 per cent for those with stage T4 cancer (p equals 0.009). Within the group with stages T2 and T3 cancer (all with proof of muscle invasion) the most striking prognostic factor was papillary surface histological findings, with local control by radiation therapy alone of 63 per cent versus 20 per cent in the group with solid or flat tumors (p equals 0.01), and corrected 5-year survival of 62 per cent (papillary) versus 0 per cent (flat or solid) (p equals 0.002). Other significant prognostic factors for 5-year survival in this group were extent of transurethral resection (54 per cent complete versus 17 per cent incomplete, p equals 0.009) and ureteral obstruction on excretory urography (47 per cent without versus 14 per cent with, p equals 0.01). Our results suggest that full-dose radiation therapy can be offered to patients with muscle-invading bladder cancer, with a relatively higher probability of success in those with less advanced tumors by clinical stage, papillary surface histological findings and no ureteral obstruction, and in whom a complete transurethral resection is possible. © 1985 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited ByCOLQUHOUN A, JONES G, MONEEF M, BOWMAN K, KOCKELBERGH R, SYMONDS R, STEWARD W and MELLON J (2018) Improving and Predicting Radiosensitivity in Muscle Invasive Bladder CancerJournal of Urology, VOL. 169, NO. 6, (1983-1992), Online publication date: 1-Jun-2003.BOCHNER B, FIGUEROA A, SKINNER E, LIESKOVSKY G, PETROVICH Z, BOYD S and SKINNER D (2018) SALVAGE RADICAL CYSTOPROSTATECTOMY AND ORTHOTOPIC URINARY DIVERSION FOLLOWING RADIATION FAILUREJournal of Urology, VOL. 160, NO. 1, (29-33), Online publication date: 1-Jul-1998.Angulo J, Sanchez-Chapado M, Lopez J and Flores N (2018) Primary Cisplatin, Methotrexate and Vinblastine Aiming at Bladder Preservation in Invasive Bladder Cancer: Multivariate Analysis on Prognostic FactorsJournal of Urology, VOL. 155, NO. 6, (1897-1902), Online publication date: 1-Jun-1996.Thrasher J and Crawford E (2018) Current Management of Invasive and Metastatic Transitional Cell Carcinoma of the BladderJournal of Urology, VOL. 149, NO. 5 Part 1, (957-972), Online publication date: 1-May-1993.Hug E, Donnelly S, Shipley W, Heney N, Kaufman D, Preffer F, Schwartz S, Colvin R and Althausen A (2018) Deoxyribonucleic Acid Flow Cytometry in Invasive Bladder Carcinoma: A Possible Predictor for Successful Bladder Preservation following Transurethral Surgery and Chemotherapy-RadiotherapyJournal of Urology, VOL. 148, NO. 1, (47-51), Online publication date: 1-Jul-1992.Prout G, Shipley W, Kaufman D, Heney N, Griffin P, Althausen A, Bassil B, Nocks B, Parkhurst E and Young H (2018) Preliminary Results in Invasive Bladder Cancer with Transurethral Resection, Neoadjuvant Chemotherapy and Combined Pelvic Irradiation Plus Cisplatin ChemotherapyJournal of Urology, VOL. 144, NO. 5, (1128-1134), Online publication date: 1-Nov-1990.Gospodarowicz M, Hawkins N, Rawlings G, Connolly J, Jewett M, Thomas G, Herman J, Garrett P, Chua T, Duncan W, Buckspan M, Sugar L and Rider W (2018) Radical Radiotherapy for Muscle Invasive Transitional Cell Carcinoma of the Bladder: Failure AnalysisJournal of Urology, VOL. 142, NO. 6, (1448-1453), Online publication date: 1-Dec-1989. Volume 134Issue 4October 1985Page: 679-683 Advertisement Copyright & Permissions© 1985 by The American Urological Association Education and Research, Inc.MetricsAuthor Information William U. Shipley More articles by this author Mary Ann Rose More articles by this author Theresa L. Perrone More articles by this author Catherine M. Mannix More articles by this author Niall M. Heney More articles by this author George R. Prout More articles by this author Expand All Advertisement PDF DownloadLoading ...